Skip to main content

Advertisement

Table 5 Summary of multivariable regression results of type 2 diabetes patients treated with lixisenatide add-on treatment to basal insulin therapy ± oral antidiabetic drugs placed in different body mass index (BMI) groups based on their baseline BMI

From: Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials

  Estimated difference 95 % Confidence limits P-value
Lower Upper
Change in HbA1c (%)     
 BMI <25 kg/m2 vs. BMI ≥35 kg/m2 0.32 0.10 0.53 0.005
 BMI 25–<30 kg/m2 vs. BMI ≥35 kg/m2 0.09 −0.09 0.26 0.32
 BMI 30–<35 kg/m2 vs. BMI ≥35 kg/m2 −0.01 −0.18 0.17 0.94
  Odds ratio Lower Upper p-value
Endpoint HbA1c <7 %
 BMI <25 kg/m2 vs. BMI ≥35 kg/m2 0.48 0.27 0.86 0.014
 BMI 25–<30 kg/m2 vs. BMI ≥35 kg/m2 0.59 0.37 0.92 0.020
 BMI 30–<35 kg/m2 vs. BMI ≥35 kg/m2 0.82 0.52 1.30 0.40
Endpoint HbA1c <7 % and no weight gain
 BMI <25 kg/m2 vs. BMI ≥35 kg/m2 0.47 0.26 0.88 0.018
 BMI 25–<30 kg/m2 vs. BMI ≥35 kg/m2 0.72 0.45 1.15 0.17
 BMI 30–<35 kg/m2 vs. BMI ≥35 kg/m2 0.79 0.49 1.29 0.35
HbA1c <7 %, no severe hypoglycemia, and no weight gain
 BMI <25 kg/m2 vs. BMI ≥35 kg/m2 0.47 0.26 0.88 0.018
 BMI 25–<30 kg/m2 vs. BMI ≥35 kg/m2 0.72 0.45 1.15 0.17
 BMI 30–<35 kg/m2 vs. BMI ≥35 kg/m2 0.79 0.49 1.29 0.35